ArticleScientifica2025
Evaluation of Xanthine Oxidase Inhibitors Febuxostat and Allopurinol on Kidney Dysfunction and Histological Damage in Two-Kidney, One-Clip (2K1C) Rats.
Article in Scientifica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- ABCG2 transporter: Structural and functional associations with gout (Review).International journal of molecular medicine · 2026Review
- Bioinformatic Analysis of Apoptosis-Related Genes in Preeclampsia Using Public Transcriptomic and Single-Cell RNA Sequencing Datasets.Journal of inflammation research · 2025Article
- Unraveling the mysteries of the gut-kidney axis: the protective role of traditional Chinese medicine in chronic kidney disease.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In chronic kidney disease (CKD), hyperuricemia is a common phenomenon, presumably due to reduced renal clearance of uric acid. This study investigated the effect of xanthine oxidase (XO) inhibitors allopurinol and febuxostat to prevent oxidative stress in the kidney of two-kidney, one-clip (2K1C) rats. In this investigation, 2K1C rats were used as an experimental animal model for kidney dysfunction. 2K1C rats were provided with food and drinking water and received febuxostat at a dose of 10 mg/kg or allopurinol at 100 mg/kg, respectively. After the treatment completion, all rats were sacrificed, and tissue samples were collected. 2K1C rats exhibited increased plasma creatinine, uric acid level, and glomerular injury assessed based on microscopic findings. Both allopurinol and febuxostat significantly normalized creatinine and uric acid levels. Furthermore, 2K1C rats showed increased lipid peroxidation (LPO), nitric oxide (NO), and advanced oxidation protein products (AOPP) alongside decreased superoxide dismutase (SOD) and catalase activity. Again, both drug treatments ameliorated these elevated oxidative stress parameters in 2K1C rats. The antioxidant genes such as Nrf-2, HO-1, and SOD were also restored in the kidneys of 2K1C rats by allopurinol and febuxostat treatment. 2K1C rats also showed increased IL-1β, IL-6, TNF-α, and NF-кB mRNA expression in the kidneys which were normalized by allopurinol and febuxostat treatment. Thus, the data suggest that XO inhibition protects kidney function potentially by restoring antioxidant enzyme function and suppressing inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.